GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Cyclically Adjusted Book per Share

BriaCell Therapeutics (BriaCell Therapeutics) Cyclically Adjusted Book per Share : $4.95 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share for the three months ended in Jan. 2024 was $-0.505. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.95 for the trailing ten years ended in Jan. 2024.

During the past 12 months, BriaCell Therapeutics's average Cyclically Adjusted Book Growth Rate was -74.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -37.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BriaCell Therapeutics was -5.80% per year. The lowest was -37.10% per year. And the median was -11.60% per year.

As of today (2024-05-22), BriaCell Therapeutics's current stock price is $1.49. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 was $4.95. BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.30.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.66. The lowest was 0.00. And the median was 0.00.


BriaCell Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted Book per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.40 51.47 44.12 28.83 12.96

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.19 16.42 12.96 8.56 4.95

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.



BriaCell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book= Book Value per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.505/125.0724*125.0724
=-0.505

Current CPI (Jan. 2024) = 125.0724.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201404 136.960 98.920 173.169
201407 -0.017 99.315 -0.021
201410 10.337 99.473 12.997
201501 5.879 98.209 7.487
201504 5.474 99.710 6.866
201507 4.104 100.579 5.103
201510 3.091 100.500 3.847
201601 1.848 100.184 2.307
201604 3.733 101.370 4.606
201607 2.586 101.844 3.176
201610 4.837 102.002 5.931
201701 4.082 102.318 4.990
201704 4.469 103.029 5.425
201707 2.125 103.029 2.580
201710 2.633 103.424 3.184
201801 1.254 104.056 1.507
201804 4.465 105.320 5.302
201807 1.784 106.110 2.103
201810 0.673 105.952 0.794
201901 -1.109 105.557 -1.314
201904 0.982 107.453 1.143
201907 -1.053 108.243 -1.217
201910 -1.130 107.927 -1.310
202001 -3.133 108.085 -3.625
202004 -3.817 107.216 -4.453
202007 -4.982 108.401 -5.748
202010 -4.364 108.638 -5.024
202101 -4.704 109.192 -5.388
202104 1.834 110.851 2.069
202107 1.812 112.431 2.016
202110 3.604 113.695 3.965
202201 2.991 114.801 3.259
202204 2.952 118.357 3.120
202207 0.666 120.964 0.689
202210 0.666 121.517 0.685
202301 -0.083 121.596 -0.085
202304 -0.380 123.571 -0.385
202307 -0.236 124.914 -0.236
202310 0.170 125.310 0.170
202401 -0.505 125.072 -0.505

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


BriaCell Therapeutics  (NAS:BCTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.49/4.95
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.66. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BriaCell Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus